OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

News

SGO and ASCO Agree on Guidelines for Common Type of Ovarian Cancer

(August 16, 2016) While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and followed by surgery. Last... 

Super Saturday Events Raise Close to $3.5 Million for OCRFA

Donna Karan, Kelly Ripa and Gabby Karan de Felice hosted Ovarian Cancer Research Fund Alliance’s (OCRFA) 19th annual Super Saturday NY. Guests in attendance included: June Ambrose, Joy Behar, Kelly Bensimon, Lorraine Bracco, Jonathan Cheban, Mayor Rudolph & Judith Giuliani, Katherine Jenkins,... 

Impact of Genetic Counseling on Testing and Surgical Prevention in High Risk Women

(Aug 1. 2016) Results of a study reported last month in Cancer show that routine referral of women at high risk for ovarian cancer to genetic counseling promotes genetic testing and prophylactic surgery. Guidelines recommend genetic counseling and testing for women who have a pedigree suggestive of an... 

Women Still Getting CA-125 and CT Testing After Ovarian Cancer, Despite Lack of Clear Benefit

(July 28, 2016)  A study published recently in JAMA Oncology showed that CA-125 tests and CT scans are routinely used in ovarian cancer surveillance testing, even though evidence has shown there is no clinical benefit to using these tests. There is no consensus on how to follow a patient in remission... 

New Treatment Shows No Benefit for Clear Cell Carcinoma     

(July 18, 2016) The first randomized phase III clinical trial to compare irinotecan and cisplatin with paclitaxel plus carboplatin in patients with clear cell carcinoma (CCC) of the ovary found no significant survival benefit between the groups. The findings of the study, which was conducted in Japan,... 

Study Finds Many Ovarian Cancer Patients Going Untreated

(July 6, 2016) Gynecologic Oncology recently published a study that found that, although surgery leads to longer survival rates, many ovarian cancer patients are not undergoing surgery, and some are not being treated at all. The researchers analyzed data from more than 210,000 women diagnosed with ovarian... 

The Effect of Oral Contraceptives on Ovarian Cancer

(June 23, 2016) The Journal of Clinical Oncology recently published a study on the role of oral contraceptives (OC) on ovarian cancer prevention. The study, which analyzed data from 21 studies with 5, 584 cases of ovarian cancer, concluded that OC reduced the risk of a variety of invasive ovarian cancers. The... 

Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

  (June 20, 2016) Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting by Susan Leighton, Ovarian Cancer Survivor and Research Advocate Since the first time I attended ASCO I have seen the number of abstracts presented about ovarian cancer increase significantly... 

OCRFA Research Sheds Light on Role of STAT3 in Ovarian Cancer

Selvendiran Karuappaiyah, PhD (June 17, 2016) An OCRFA funded study recently published in Oncogene investigated the role that protein STAT3 plays in the activation and metastasis of ovarian cancer cells. Many women with ovarian cancer develop fluid in the abdomen, which contains cancer cells. Those cells,... 

OCRFA Founder Sol Schreiber passes away

(6/9/16) With deep sorrow, Ovarian Cancer Research Fund Alliance mourns the passing of our beloved founder and Chairman Emeritus, Sol Schreiber. We are profoundly grateful for his foresight in founding this organization, as well as his unwavering leadership through the years. His steady commitment to...